What is the confirmed market size and growth trajectory for the veterinary anti-infectives market?
The market was valued at USD 8.5 billion in 2025 and is projected to grow at a CAGR of 6.8% to USD 15.37 billion by 2035. Anti-infectives are the second-largest animal health product category after vaccines. Companion animal therapeutic anti-infectives are the fastest-growing segment by value. Livestock anti-infective volumes decline under stewardship but therapeutic value sustains. North America and Europe lead; Asia-Pacific grows. Cephalosporins are the highest-value anti-infective class.

How does ceftiofur exemplify the premium therapeutic anti-infective market?
Ceftiofur — Zoetis’s top-five revenue product serving cattle, swine, and poultry respiratory disease treatment — is a third-generation cephalosporin on the WHO critically important antimicrobial list, requiring veterinary prescription in most markets and commanding premium pricing above generic first-generation cephalosporins. Ceftiofur’s top-five revenue position at a USD 9.5 billion company confirms the commercial scale of premium therapeutic anti-infective demand even within the stewardship regulatory environment.

How does EU Regulation 2019/6 restructure the farm animal anti-infective market?
EU Regulation 2019/6 — effective January 2022 — restricts prophylactic antibiotic use and limits metaphylactic use to defined clinical justification criteria. This regulation has reduced EU livestock antibiotic use by approximately 40% from 2014 peak levels while sustaining therapeutic treatment volumes, creating a more concentrated, prescription-quality anti-infective market where remaining use is clinically justified, documented, and higher-value than the historical blanket prophylaxis applications.

How does Zoetis’s precision livestock farming technology support antimicrobial stewardship?
Zoetis’s precision livestock farming technologies — individual animal biodevice monitoring, genetic health risk prediction, and data analytics — enable early individual animal disease identification that triggers targeted therapeutic anti-infective treatment before group treatment becomes necessary. This precision approach reduces anti-infective volumes through targeted use while sustaining clinical health outcomes — demonstrating that precision technology and anti-infective stewardship are commercially complementary.

What companion animal anti-infective categories are growing fastest?
Companion animal anti-infectives for skin and soft tissue infections (amoxicillin-clavulanate, cephalexin, cefpodoxime) and urinary tract infections are growing fastest from increasing veterinary diagnostic testing intensity that identifies bacterial infections requiring therapeutic treatment. IDEXX reference laboratory urine culture and sensitivity testing and MRSP molecular diagnostics create diagnostic-driven anti-infective prescribing demand sustaining companion animal market growth above livestock volume declines.

How does Elanco’s farm animal focus define its anti-infective market position?
Elanco’s farm animal portfolio — serving cattle, poultry, swine, and sheep with anti-infective products for respiratory disease, mastitis treatment, and enteric disease management — across more than 90 countries represents a global farm animal anti-infective distribution footprint sustaining therapeutic demand across the full range of livestock anti-infective clinical applications aligned with global AMR reduction goals.